Immunic (IMUX) Other financing activities (2013 - 2026)

Immunic has reported Other financing activities for 13 years, with the latest figure at $187.3 million in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to $187.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.4 million (up 243335.06% YoY) and the FY2025 annual result came in at $182000.0, up 136.36% from the prior year.
• Other financing activities grew to $187.3 million in Q1 2026 per IMUX's latest filing, from $59000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $187.3 million in Q1 2026 and troughed at -$125000.0 in Q4 2022.
• A 5-year average of $18.8 million and a median of $55000.0 in 2023 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 920.0% in 2023, down 64.0% in 2023.
• Over 5 years, Other financing activities stood at -$125000.0 in 2022, then jumped by 64.0% to -$45000.0 in 2023, then jumped by 271.11% to $77000.0 in 2024, then retreated by 23.38% to $59000.0 in 2025, then jumped by 317294.92% to $187.3 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $187.3 million, $59000.0, and $123000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.